Genome & Company

314130 · KQ · Healthcare / Biotechnology

3,150.00KRW-125.00 (-3.82%)

Price History

Full chart

Market Stats

Previous Close3,275.00

Open3,260.00

Day Range3,135.00 – 3,435.00

52-Week Range2,585.00 – 10,180.00

Volume205.34K

Market Cap247.12B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.38

50-Day Avg3,904.50

200-Day Avg5,950.23

About

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements. In addition, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD), as well as disorders related to gut-injury, including Necrotizing Enterocolitis (NEC). The company was founded in 2015 and is headquartered in Suwon-si, South Korea.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Yoo Seok Hong
Employees97
Headquarters7th and 8th floors, Suwon-si, South Korea, Korea
Websitehttps://genomecom.co.kr

Leadership

Mr. Yoo Seok HongCo-Chief Executive Officer & Director · b. 1964
Mr. Jisoo Pae M.D.Founder, Co-CEO & Representative Director · b. 1971
Mr. Han-Su ParkFounder, Co-CEO, CTO & Representative Director · b. 1973
Jae-wook JungCFO & Internal Accounting Manager
Gyeong-yeong MinHead of Accounting
Ms. Hyun-kyung YooMD and Head of Pharmacology & Toxicology Research Lab · b. 1974
Ms. Jin-kyung SeoMD & Head of Consumer Business Group · b. 1979

Financials

Income Statement

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	451.25M	14.08B	14.30B	27.74B	24.59B
Growth (%)	-	+3021.27%	+1.50%	+94.07%	-11.38%
Cost of Revenue	77.01M	8.49B	10.23B	12.07B	11.18B
Gross Profit	374.24M	5.60B	4.06B	15.67B	13.41B
Gross Margin	82.93%	39.74%	28.43%	56.48%	54.53%
Operating Expense	36.46B	63.11B	61.48B	48.24B	42.64B
Operating Income	-36.09B	-57.51B	-57.42B	-32.57B	-29.23B
Operating Margin	-7997.20%	-408.34%	-401.63%	-117.38%	-118.90%
EBITDA	-	-48.40B	-41.84B	-17.23B	2.72B
EBITDA Margin	-	-343.61%	-292.70%	-62.09%	11.08%
Net Income	-34.12B	-51.84B	-47.47B	-20.11B	-6.43B
Net Income Margin	-7560.62%	-368.05%	-332.02%	-72.49%	-26.14%
R&D	21.26B	36.79B	25.67B	13.38B	11.95B
R&D as % of Total Revenue	4712.15%	261.23%	179.53%	48.22%	48.60%
Interest Expense	54.92M	175.00M	1.74B	3.54B	4.72B
Interest Expense % of Total Revenue	12.17%	1.24%	12.16%	12.76%	19.20%

Balance Sheet

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	137.22B	173.00B	162.06B	147.33B	145.01B
Total Liabilities	23.82B	75.70B	99.63B	99.02B	30.43B
Total Equity	92.73B	97.30B	62.43B	48.31B	105.78B
Cash	36.05B	72.22B	56.36B	65.55B	15.60B

Cash Flow

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-26.16B	-36.00B	-31.00B	-7.61B	-18.39B
Investing Cash Flow	-	-6.38B	-15.43B	11.55B	-
Financing Cash Flow	-	78.55B	30.57B	5.25B	-
Capital Expenditure	3.38B	7.28B	19.04B	4.19B	497.66M
Free Cash Flow	-29.54B	-50.83B	-51.27B	-20.52B	-18.88B
FCF to OCF	112.92%	141.18%	165.39%	269.63%	102.71%

Earnings

Report Date	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	Sep 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	-387.31	-274.69	-244.24	-357.03	-392.90	-355.53	-561.86	-430.06	-513.29	-364.20	-207.61	-319.29	-790.00	-271.64	-29.40	-277.51	-218.45	-227.29	-207.24	-242.13	421.53	-182.17	-997.08
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap247.12B

Enterprise Value183.82B

Trailing P/E0.00

Forward P/E0.00

Price / Sales10.18

Price / Book3.26

Revenue (TTM)24.46B

Gross Profit (TTM)13.33B

EBITDA-23.17B

Profit Margin-169.09%

Operating Margin-127.50%

Return on Equity-47.10%

Return on Assets-13.75%

Shares Outstanding45.18M

Shares Float33.64M

Beta0.38

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Aug 6, 20242:1